Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1995-2-7
|
pubmed:abstractText |
The extent of lymphadenectomy in the treatment of non-small cell lung cancer is still a matter of controversy. While some centers perform mediastinal lymph node sampling with resection of only suspicious lymph nodes, others recommend a radical, systematic mediastinal lymphadenectomy (LA) to improve survival and achieve a better staging. Herein we report on the impact of LA on tumor staging in a controlled, prospective, randomized clinical trial comparing lymph node sampling and LA in a total of 182 patients with operable non-small cell lung cancer. Regardless of the type of lymphadenectomy performed, the percentage of patients with pathologic N1 or N2 (sampling: n = 23, 23.0%; LA: n = 22, 26.8%) disease was very similar in both groups, indicating that systematic radical lymphadenectomy is not an essential prerequisite to determine the N stage of a patient. In contrast, the number of patients detected to have lymph node involvement at multiple levels was significantly increased by LA. In the lymph node sampling group only 4 of 23 patients (17.4%) with N2 disease were found to have more than one lymph node level involved, whereas LA results in the detection of excessive N2 disease in 12 of 21 patients (57.2%; p = 0.007), which was associated with a shorter distant metastases-free (p = 0.021) and overall survival. In conclusion, LA is not essential to determine the N stage of a patient, but results in a more detailed staging of the N2 region, which is of prognostic significance. Therefore, it might be useful to identify patients with a higher risk for tumor relapse.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0003-4975
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
59
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
209-14
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:7818326-Adult,
pubmed-meshheading:7818326-Aged,
pubmed-meshheading:7818326-Aged, 80 and over,
pubmed-meshheading:7818326-Biopsy,
pubmed-meshheading:7818326-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:7818326-Female,
pubmed-meshheading:7818326-Humans,
pubmed-meshheading:7818326-Lung Neoplasms,
pubmed-meshheading:7818326-Lymph Node Excision,
pubmed-meshheading:7818326-Lymph Nodes,
pubmed-meshheading:7818326-Male,
pubmed-meshheading:7818326-Mediastinum,
pubmed-meshheading:7818326-Middle Aged,
pubmed-meshheading:7818326-Neoplasm Staging,
pubmed-meshheading:7818326-Prognosis,
pubmed-meshheading:7818326-Prospective Studies,
pubmed-meshheading:7818326-Survival Rate
|
pubmed:year |
1995
|
pubmed:articleTitle |
Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer.
|
pubmed:affiliation |
Department of Surgery, University of Munich, Germany.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|